Alleviating effect of active hexose correlated compound (AHCC) for anticancer drug-induced side effects in non-tumor-bearing mice

Kota Shigama, Akihiro Nakaya, Koji Wakame, Hiroshi Nishioka* and Hajime Fujii

Amino Up Chemical Co., Ltd., 363-32 Shin-ei, Kiyota, Sapporo 004-0839, Japan

*Correspondence to: Hiroshi Nishioka, Amino Up Chemical Co., Ltd., 363-32 Shin-ei, Kiyota, Sapporo 004-0839, Japan. Telephone: +81-11-889-2233; Fax: +81-11-889-2375. E-mail: nishioka@aminoup.co.jp

(Received March 2, 2009; accepted March 19, 2009)

INTRODUCTION

The incidence of neoplasm has been reported to be increasing in numerous countries including Japan (1,2). Chemotherapy plays an important role in the treatment of various kinds of cancer such as hematological malignancies. However, chemotherapy is often difficult for patients, in part due to multiple side effects including hair loss, hematological and gastrointestinal toxicities, hepatotoxicity, nephrotoxicity, and neurotoxicity. These side effects lower the quality of life in cancer patients, and they often trigger reductions in the dosage, frequency and duration of chemotherapy, even when it is not therapeutically optimal. Furthermore, chemotherapy inflicts considerable distress, anxiety and depression in almost all cancer patients (3). While the current strategy of anticancer drugs is focused on molecular-targeted agents with high selectivity, such as gefitinib (4,5) and erlotinib (6) that are epidermal growth factor receptor inhibitors, these newer drugs continue to be associated with problems, including dermatologic (7,8) and ocular side effects (9).

One approach to alleviate chemotherapy-induced side effects is the use of complementary and alternative medicine (CAM) that has received great attention. Many cancer patients use CAM with the hope of reducing the side effects of anticancer drugs, and to obtain additional anticancer effects through the boosting of the immune system (10-13). A survey in Japan reported that the prevalence of CAM use was 44.6 percent in cancer patients, with the most frequently used CAM...
therapy being dietary supplements of mushrooms such as agaricus \textit{(Agaricus blazei Murill)} and active hexose correlated compound (AHCC) (14).

AHCC is a mixture of polysaccharides, amino acids, lipids and minerals derived from cultured broth of the basidiomycete mushroom, \textit{Lentinula edodes} (shiitake). The predominant component of AHCC is oligosaccharides, which contain α-1, 4 glucans and partially acetylated α-1, 4 glucans with a mean molecular weight of 5,000 Daltons. Investigators have reported that AHCC can increase the number and function of dendritic cells and NK cell activity in adult human (15,16), and enhance both the activation and proliferation of CD4+ and CD8+ T cells in mice (17). In tumor-bearing rodent models, AHCC strengthened the chemotherapeutic effects of UFT and cisplatin for mammary adenocarcinoma SST-2 cells and Colon-26 tumor cells, respectively (18,19). AHCC has been reported to be safe for human consumption, based on the results from several pre-clinical studies and a Phase I study using healthy volunteers (20). No inhibition of CYP450 activity was observed in presence of AHCC, however, AHCC was a substrate of CYP450 2D6. The CYP450 induction metabolism assays indicate that AHCC is an inducer of CYP450 2D6. AHCC does have the potential for drug-drug interactions involving CYP450 2D6 such as ondansetron, however overall data suggests that AHCC would be safe to administer with most other chemotherapy agents that are not metabolized via the CYP450 2D6 pathway (21). Furthermore, two clinical studies among liver cancer patients showed a significant increase in survival rate among those taking AHCC (22,23).

While the immunomodulating actions and anti-tumor effects of AHCC have been demonstrated, the effect of AHCC on anticancer drug-induced toxicities is not well characterized. In the present study, we investigated the influence of AHCC on some of the side effects caused by monotherapy with paclitaxel, or multi-drug chemotherapy in non-tumor-bearing mice, but not tumor-bearing mice because of estimating intrinsic body weight change and mortality rate associated with anticancer agents.

\section*{MATERIALS AND METHODS}

\section*{Reagents}

AHCC, manufactured by Amino Up Chemical Co., Ltd. (Japan), was produced from cultured broth of the basidiomycete mushroom, \textit{Lentinula edodes}, in a manufacturing process according to Good Manufacturing Practice (GMP) standards for dietary supplements, and ISO9001 and ISO22000 standards. Following precultivation in flasks, the basidiomycete was cultured in large (15 tons) tanks for 45 days, and then AHCC was obtained through filtration, sterilization, concentration and freeze-drying. Paclitaxel (TAX), doxorubicin (DXR) and cyclophosphamide (CY) were purchased from Sigma-Aldrich Japan (Japan), Cisplatin (CDDP), 5-fluorouracil (5FU) and irinotecan (CPT) are commercially available drugs as Randa Inj. (NIPPPON KAY-AKU CO., LTD., Japan), 5-FU Injection (Kyowa Hakko Kirin Co., Ltd., Japan) and CAMPTO Inj. (YAKULT HONSHA CO., LTD., Japan), respectively, and these drugs all were obtained from JUNSEI CHEMICAL CO., LTD. (Japan).

\subsection*{Animals}

SPF male ddY mice were purchased from Japan SLC, Inc. (Japan) and studied at five weeks of age. The animals were maintained in a temperature- and humidity-controlled room at 23 ± 1°C and 55-60%, respectively, under a 12-hour light-dark cycle (lights on 08:00 to 20:00), and were fed a standard pelleted rodent chow (CE-2; CLEA Japan Inc., Japan) and water \textit{ad libitum}. Mice in each experiment were divided into three groups: control, anticancer drug(s) alone, and AHCC plus anticancer drug(s).

\subsection*{Treatments}

The anticancer drugs used in this study were TAX, CDDP, 5FU, CPT, DXR and CY. TAX or CY was dissolved in DMSO and mixed with saline prior to administration. The commercialized CDDP, 5FU or CPT solution was directly injected into mice. DXR was dissolved in saline followed by the treatment. AHCC was dissolved in saline just before the supplementation. The anticancer agents and AHCC were given to mice intraperitoneally and by gavage, respectively. The study consisted of five experiments (Exp. 1 to Exp. 5). The experimental designs are briefly outlined in Table 1. All experiments had a control group that was treated with same regimen of anticancer-treated groups with and without AHCC, except for administration of vehicle instead of anticancer drugs and AHCC. In Exp. 1, 15 mg/kg of TAX was administered into mice at days 8, 11, 15, 18 and 22 (a total of 5 injections). AHCC was given daily at a dose of 500 mg/kg from day 0 to day 25. In Exp. 2, mice were co-treated with 20 mg/kg of TAX and 8 mg/kg of CDDP once a week for 2 weeks (days 7 and 14). Supplementation with AHCC (1 g/kg) was commenced 7 days prior to the first treatment with anticancer drugs and was continued until day 18. Two experiments (Exp. 3; 100 mg/kg of 5FU plus 50 mg/kg of CPT, and Exp. 4; 8 mg/kg of CDDP plus 100 mg/kg
AHCC for anticancer drug-induced side effects in non-tumor-bearing mice

Table 1. Experimental designs

<table>
<thead>
<tr>
<th>Experiment #</th>
<th>Treatment</th>
<th>Drug dosing schedule (dose and days)</th>
<th>AHCC dosing schedule (dose and days)</th>
<th>Number of mice*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exp. 1</td>
<td>TAX</td>
<td>a) 15 mg/kg Day 8, 11, 15, 18 and 22</td>
<td>None</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>a) 15 mg/kg Day 8, 11, 15, 18 and 22</td>
<td>500 mg/kg Day 0 to 25</td>
<td>8</td>
</tr>
<tr>
<td>Exp. 2</td>
<td>TAX + CDDP</td>
<td>a) 20 mg/kg + b) 8 mg/kg Day 7 and 14</td>
<td>None</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>a) 20 mg/kg + b) 8 mg/kg Day 7 and 14</td>
<td>1 g/kg Day 0 to 18</td>
<td>9</td>
</tr>
<tr>
<td>Exp. 3</td>
<td>5FU + CPT</td>
<td>c) 100 mg/kg + d) 50 mg/kg Day 7 and 14</td>
<td>None</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>c) 100 mg/kg + d) 50 mg/kg Day 7 and 14</td>
<td>1 g/kg Day 0 to 21</td>
<td>10</td>
</tr>
<tr>
<td>Exp. 4</td>
<td>CDDP + 5FU</td>
<td>b) 8 mg/kg + c) 100 mg/kg Day 7 and 14</td>
<td>None</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>b) 8 mg/kg + c) 100 mg/kg Day 7 and 14</td>
<td>1 g/kg Day 0 to 21</td>
<td>11</td>
</tr>
<tr>
<td>Exp. 5</td>
<td>DXR + CY</td>
<td>e) 8 mg/kg + f) 120 mg/kg Day 7</td>
<td>None</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>e) 8 mg/kg + f) 120 mg/kg Day 7</td>
<td>360 mg/kg Day 0 to 21</td>
<td>10</td>
</tr>
</tbody>
</table>

a) TAX: paclitaxel,  
b) CDDP: cisplatin,  
c) 5FU: 5-fluorouracil,  
d) CPT: irinotecan,  
e) DXR: doxorubicin,  
f) CY: cyclophosphamide.

* Number of mice in control group was as same as that of anticancer drug-treated group without AHCC.

of 5FU) were conducted in accordance with a similar schedule, where dual drugs were co-injected on days 7 and 14, and 1 g/kg of AHCC was successively administered from day 0 to day 21. In Exp. 5, mice received a single administration of DXR (8 mg/kg) and CY (120 mg/kg) at day 7, and daily supplementation with 360 mg/kg of AHCC from day 0 to day 21. In each experiment, animals were killed under anesthesia to collect blood and bone marrow cells on the final day of AHCC administration.

In past studies, the effect of AHCC was assessed at a dosage range from 100 mg/kg to 1 g/kg (17-19,24). Hence, the working dose of AHCC in this study was chosen within this range. The dose and schedule of anticancer drugs used in this study were based on previous investigations (25-29) with some modifications. All experiments were approved by the Animal Care Committee of Amino Up Chemical Co., Ltd.

Evaluation of Parameters

The following parameters were assessed: body weight, liver function (serum AST and ALT), kidney function (blood urea nitrogen (BUN) and serum creatinine), bone marrow suppression (total white blood cell count and bone marrow cell viability), and mortality rate. Body weight was measured twice a week. AST (GOT) and ALT (GPT), BUN, and serum creatinine were measured using Transaminase CII-test WAKO, Urea Nitrogen B-test WAKO, and Creatinine-test WAKO assay kits (Wako Pure Chemical Industries Limited, Japan), respectively.
Blood samples collected from the heart were diluted to 1:10 with Turk solution (Wako Pure Chemical Industries Limited, Japan) to determine the number of white blood cells in accordance with the Nageotte chamber counting procedure (30). Bone marrow cells collected from mouse femora were suspended in 0.83% NH₄Cl solution to hemolyze red blood cells and incubated at 37°C for 10 min. After centrifugation, the cells were prepared at a concentration of 1×10⁷ cells/ml in DMEM supplemented with 10% FBS. A 100-µl aliquot of the suspension was cultured in a 96-well plate for 3 days, and viability (percent of control group) of bone marrow cells was estimated using the MTT assay. Mortality data were collected daily.

**Statistical Analysis**

Experimental data except for mortality rate are shown as mean ± SEM. Data were analyzed by one-way analysis of variance (ANOVA). Fisher’s Protected Least Significance Difference (PLSD) was used as a post hoc test, and values of p less than 0.05 were determined to be statistically significant.

**RESULTS**

**Change of Body Weight**

The change in body weight was calculated the ratio of body weight gain in the treated groups compared to the gain in their respective control (non-treatment) groups on the final day of each experiment (Figure 1). Interestingly, treatment with TAX alone significantly increased body weight compared to either the control group or the AHCC plus TAX group. The increase in body weight was likely due to dyschezia since the large bowel was visually swollen with feces when mice were dissected at day 25. AHCC administration suppressed TAX-induced body weight elevation, suggesting that AHCC might improve this disorder. All multi-drug therapies predictably decreased body weight gain compared to the respective control group, with the most pronounced decrease in body weight gain noted for the combinations with CDDP (TAX plus CDDP, and CDDP plus 5FU). Supplementation with AHCC tended to prevent body weight loss although the effect was not statistically significant. Though TAX alone (five-time repeated dose of 15 mg/kg; Exp. 1) resulted in weight gain, the multi-drug treatment with TAX (twice weekly dose of 20 mg/kg) plus CDDP (Exp. 2) decreased body weight and no dyschezia was noted when the animals were dissected; it is possible that this difference in findings was due to the lower dosage of TAX used in the second experiment.

**Hepatotoxicity and Nephrotoxicity**

Serum AST and ALT levels were significantly increased in the TAX alone group (p<0.05 vs control; Table 2). AHCC administration reduced both levels, with the reduction in ALT being statistically significant (p<0.05; Table 2). In contrast, TAX plus CDDP treatment did not change serum AST and ALT concentrations, and all values were in the normal range (data not shown). As noted above, the differences between TAX alone and TAX+CDDP may be due to the different doses of TAX used in Exp. 1 and 2.

In humans, CDDP treatment can result in renal dysfunction, which is a dose limiting factor. In this study,
the kidney function parameters of BUN and serum creatinine were evaluated in the two combination groups with CDDP at the end of Exp. 2 and Exp. 4. The concentrations of BUN and serum creatinine were significantly increased in both CDDP-treated groups compared to the control group ($p<0.01$; Table 3). AHCC administration attenuated the levels of BUN and serum creatinine, and a significant difference in both the BUN (Exp. 2 and Exp. 4) and creatinine (Exp. 2) level was measured.

**Bone Marrow Suppression and Mortality Rate**

All treatments with dual anticancer drugs caused significant bone marrow suppression as measured by leukocyte count and bone marrow cell viability ($p<0.01$ vs control; Figures 2A and 2B). Supplementation with AHCC significantly improved the reduction of leukocytes in all groups except for TAX+CDDP, though the levels did not completely return to control values for any of the treatments. Bone marrow cell viability was also depressed by single and all multiple treatments, and AHCC supplementation significantly reversed this trend ($p<0.01$), though the amelioration did not show complete recovery.

The drugs were lethal to 20 to 30 percent of the animals given the anticancer drug(s) alone, except for the TAX+CDDP group, and addition of AHCC resulted in either reduction or elimination of mortality (Table 4).

**DISCUSSION**

Cancer treatment including mono- and combination chemotherapies reliably improves the disease-free

---

### Table 3. BUN, serum creatinine and the ratio on the final day of Exp. 2 and 4

<table>
<thead>
<tr>
<th>Group</th>
<th>BUN (mg/dL)</th>
<th>Creatinine (mg/dL)</th>
<th>BUN/Creatinine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>24.5 ± 0.9</td>
<td>0.59 ± 0.02</td>
<td>36.2 ± 1.6</td>
</tr>
<tr>
<td>TAX+CDDP</td>
<td>34.9 ± 1.7</td>
<td>0.93 ± 0.03</td>
<td>37.9 ± 2.1</td>
</tr>
<tr>
<td>AHCC+TAX+CDDP</td>
<td>30.5 ± 1.5</td>
<td>0.78 ± 0.03</td>
<td>39.5 ± 2.6</td>
</tr>
<tr>
<td>Control</td>
<td>23.8 ± 1.3</td>
<td>0.59 ± 0.02</td>
<td>41.6 ± 2.5</td>
</tr>
<tr>
<td>CDDP+5FU</td>
<td>35.3 ± 6.3</td>
<td>0.77 ± 0.08</td>
<td>45.9 ± 6.2</td>
</tr>
<tr>
<td>AHCC+CDDP+5FU</td>
<td>25.4 ± 1.1</td>
<td>0.66 ± 0.03</td>
<td>38.5 ± 1.3</td>
</tr>
</tbody>
</table>

All values are expressed as mean ± SEM. $a) p<0.01$ vs control, $b) p<0.05$ vs AHCC+TAX+CDDP, $c) p<0.01$ vs control, AHCC+TAX+CDDP, $d) p<0.05$ vs control, $e) p<0.01$ vs control, AHCC+CDDP+5FU, $f) p<0.01$ vs control.

---

**Figure 2. Ameliorative effect of AHCC for anticancer drug(s)-induced myelosuppression.**

Bone marrow suppression was determined using two parameters that were total white blood cell (WBC) count (A) and bone marrow cell viability (B). Both assessments were carried out when mice were sacrificed at the end of each experiment, and the evaluation methods are briefly described in the section, Materials and Methods. The values are expressed as the ratio to control (% of control). * $p<0.01$ vs control, ** $p<0.01$ vs control, $p<0.05$ vs AHCC supplemented group, $f) p<0.01$ vs control, AHCC supplemented group.
Table 4. Mortality rate in the treatment groups without or with AHCC

<table>
<thead>
<tr>
<th>Treatment</th>
<th>None</th>
<th>+ AHCC</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAX</td>
<td>25% (2/8)</td>
<td>0% (0/8)</td>
</tr>
<tr>
<td>TAX+CDDP</td>
<td>0% (0/9)</td>
<td>0% (0/9)</td>
</tr>
<tr>
<td>5FU+CPT</td>
<td>30% (3/10)</td>
<td>0% (0/10)</td>
</tr>
<tr>
<td>CDDP+5FU</td>
<td>30% (3/10)</td>
<td>9% (1/11)</td>
</tr>
<tr>
<td>DXR+CY</td>
<td>20% (2/10)</td>
<td>0% (0/10)</td>
</tr>
</tbody>
</table>

The values in parenthesis represent dead mice/total mice.

and overall survival in cancer patients, but the clinical usefulness is frequently limited by side effects. This study was designed to investigate the impact of AHCC in terms of side effects induced by anticancer drugs in animal models.

In humans, major TAX-related side effects include peripheral neuropathy, myelotoxicity, granulocytopenia, bradycardia, hypotension, arthralgia, myalgia and hypersensitivity (31,32). These side effects were not duplicated in Exp. 1, but observable side effects included dyschezia, hepatotoxicity and bone marrow suppression. Supplementation with AHCC significantly alleviated the hepatotoxicity and myelosuppression and showed a tendency to reduce the severity of dyschezia. In addition to monotherapy, current clinical oncology practice employs a strategy to use multiple anticancer agents with distinct molecular mechanisms, anticipating higher chemotherapeutic efficacy and/or lower toxicity. In the present study, we also assessed the action of AHCC on four combination treatments, which were selected because the multi-drug therapies tested here are commonly used for treatment of non-small-cell cancer of the lung (33,34), and cancer of the ovary (35), colon (36), gastrointestinal tract (37), liver (38), cervix (39) and breast (40) as a first- or second-line treatment. The most noteworthy effect of AHCC was an improvement in terms of side effects induced by anticancer drugs in animal models (51-53). Maitake β-glucans (MBG) was found to promote bone marrow cell viability and protect the bone marrow stem cell colony formation unit from DXR-induced hematopoietic toxicity (54). The recent study has reported that MBG induces hematopoietic stem cell proliferation and differentiation and acts to replace and induce G-CSF (55). It is speculated that the effect of AHCC on alleviating myelosuppression might be mediated by the mechanism similar to MBG although the predominant polysaccharide component of AHCC is partially acetylated α-glucans but not β-glucans. In future, further studies are needed to elucidate the precise mechanism(s) of action on improving bone marrow suppression as well as hepatotoxicity and nephrotoxicity. With increasing use of CAM, it is important to address safety issues and interactions between CAM products and conventional treatments (56,57) including chemotherapy, surgical resection, radiotherapy, and increasingly, targeted molecular therapies. The safety of AHCC in cancer patients and healthy volunteers has been previously reported (15, 16, 20, 22, 23). The current study assessing the role of AHCC in reducing chemotherapy-related side effects in animal models suggests that AHCC may be safe to administer with the drugs tested, and perhaps other chemotherapy agents that are not metabolized via the CYP450 2D6 pathway (21). For many cancer patients, CAM approaches are pursued in an attempt to maximize the efficacy of conventional modalities, as well as to reduce treatment-related symptoms and other side effects that diminish their quality of life (10-14). Cancer patients also use CAM products such as AHCC for strengthening their overall function to recover from the debility of cancer treatment and supporting their ability to fight against cancer (58-60).
CONCLUSION

The present study was conducted to assess whether AHCC reduces anticancer drug-induced toxicities including body weight loss, liver and kidney damages, myelosuppression, and mortality in non-tumor-bearing mice. As a result, AHCC significantly alleviated hepatotoxicity, nephrotoxicity, bone marrow suppression and overall mortality, and showed the possibility to reduce the severity of dyschezia. If these results are extended to humans, AHCC might contribute to improved quality of life and well-being of cancer patients undergoing chemotherapy.

ACKNOWLEDGMENT

We thank Dr. Robert M. Hackman and Dr. Carl L. Keen, University of California-Davis, and Dr. Judith A. Smith, University of Texas, MD Anderson Cancer Center, for providing greatly appropriate suggestions and comments.

REFERENCES


AHCC for anticancer drug-induced side effects in non-tumor-bearing mice


AHCC for anticancer drug-induced side effects in non-tumor-bearing mice


